Skip to main content
. 2021 Feb 19;11(2):344. doi: 10.3390/diagnostics11020344

Figure 3.

Figure 3

Progression-free survival (PFS) subgroup analysis of key Hippo signaling genes for OC patients, according to high or low expression level based on tumor stage. PFS of key Hippo signaling genes (MST1, LATS1, LATS2, TAZ, MST1, and TEF) for OC patients, grouped on stage I + II and III + IV, respectively. Survival curves of OC patients according to the expression of the Kaplan–Meier plotter (https://kmplot.com/analysis/index.php?p=service, accessed on 4 January 2021) based on TCGA patients, a log-rank test was used (LATS1 high/low, I + II p = 0.26 and III + IV p = 0.13; TP53 high/low I + II p = 0.014 and III + IV p = 0.0057; LATS2 low/high, I + II p = 0.13 and III + IV p = 8.1 × 10−6; TAZ low/high I + II p = 0.031 and III + IV p = 0.06; MST1 low/high, I + II p = 0.046 and III + IV p = 0.35; TEF high/low, I + II p = 0.075 and III + IV p = 0.0022).